The U.S. government will give pharmaceutical company Moderna $176 million for a High Path Avian Flu vaccine, according to Reuters.
It uses the same technology as the COVID-19 vaccine, and Moderna began development and testing it last year on adults.
“mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic,” said Moderna CEO Stephane Bancel.
So far, four agriculture workers have contracted the virus since 2022.
Related Stories
To mark the end of National Chicken Month, we take a look at how the U.S. poultry industry is making a slow and steady recovery following the widespread outbreak of High-Path Avian Flu (HPAI) in 2022 that devastated commercial flocks across the country.
Egg prices have been on a roller coaster this year, soaring sky-high and falling back down to Earth in just a few months.
In June, prices were down 77% compared to the highest weekly price in 2022.
According to the USDA Outlook Board, margins could improve for producers depending on a decrease in cases of High-Path Avian Flu (HPAI).
